Recent advances in multidisciplinary management of hepatocellular carcinoma

Table 3 Combined sorafenib plus systemic anticancer therapy for unresectable hepatocellular carcinoma

Ref.	Chemotherapeutic agent	Type of study	Patients, n	Median OS, mo	DCR, %	Median PFS, mo
Abou-Alfa et al[160]	Doxorubicin	Multicenter randomized prospective phase II	47 vs 49	13.7 vs 6.5	62	6.0 vs 2.7
Hsu et al[166]	Tegafur/uracil	Prospective phase II	53	7.4	57	3.7
Prete et al[161]	Long-acting octreotide	Prospective phase II	50	12	76	7
Abou-Alfa et al[165]	PR-104	Prospective phase I	14	NR	50	NR
Lee et al[164]	S-1 fluoropyrimidines	Prospective phase I	20	10.4	52.9	3.9
Petrini et al[163]	5-Fluorouracil	Prospective phase II	39	13.7	48.7	7.5